Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2305]

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin...

Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada

$Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma ( Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada )$

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO...

Prof Robert Huddart and Dr Ignacio Durán

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020 ( Prof Robert Huddart and Dr Ignacio Durán )

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Background of the KEYLYNK-007 trial for advanced solid tumours

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Background of the KEYLYNK-007 trial for advanced solid tumours ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma

Dr Katie Kelley - University of California San Francisco, San Francisco, USA

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma ( Dr Katie Kelley - University of California San Francisco, San Francisco, USA )

COVID-19 and breast cancer: How should we treat our patients?

Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain

COVID-19 and breast cancer: How should we treat our patients? ( Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain )

Updated results from KEYNOTE-426 for metastatic kidney cancer

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

Updated results from KEYNOTE-426 for metastatic kidney cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung...

Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer ( Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA )

More from ecancer